1582P - NeuroCog-FX Study: A Multicenter Cohort Study on Cognitive Dysfunction in Patients with Early Breast Cancer

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Psychosocial Aspects of Cancer
Breast Cancer
Supportive and Palliative Care
Presenter Oliver Rick
Citation Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388
Authors O. Rick1, M. Reuß-Borst2, T. Dauelsberg3, H. Hass4, V. König5, R. Caspari6, G. Götz-Keil7, J. Pfitzner8, C. Kerschgens9, K. Fliessbach10, C. Hoppe10
  • 1Oncological Rehabilitation, Klinik Reinhardshoehe, 34537 - Bad Wildungen/DE
  • 2Oncological Rehabilitation, Klinik am Kurpark, 97688 - Bad Kissingen/DE
  • 3Oncological Rehabilitation, Winkelwald Klinik, 77787 - Nordrach/DE
  • 4Oncological Rehabilitation, Klinik Scheidegg, 88175 - Scheidegg/DE
  • 5Oncological Rehabilitation, Klinik Oexen, 32549 - Bad Oeynhausen/DE
  • 6Oncological Rehabilitation, Bayerwaldklinik, Cham/DE
  • 7Bad Nauheim, Klinik am Kurpark, Bad Nauheim/DE
  • 8Oncological Rehabilitation, Klinik Graal Müritz, Graal Müritz/DE
  • 9Oncological Rehabilitation, Vivantes Klinikum, Berlin/DE
  • 10Neurology, University Bonn, Bonn/DE



Many breast cancer patients complain about cognitive dysfunction (CD) with mnestic and attentional deficits. These complaints persist even after completion of therapy in approximately one third of the patients and affects both social life and working capacity. The exact nature and genesis of CD in breast cancer patients is still not fully understood and risk factors are not yet described.


To determine CD and risk factors, we used the computer-based neuropsychological test NeuroCog-FX during a three weeks oncological rehabilitation in breast cancer patients. Eight subtests addressed attention, working memory, verbal and figural memory, and language. Test duration was


From February 2013 to December 2014 a total of 476 patients were recruited in 9 oncological rehabilitation centers in Germany. NeuroCog-FX was used to examine 439 patients. Median age was 50 years (range: 24-62 years); 93% of patients had early tumor stage (T0-T2) and 67% were node-negative. Sixty-one percent of the patients received chemotherapy while 84% of the subjects underwent radiotherapy. CD was found in 59% and a moderate to severe depression in 38% of the patients. The severity of depression was correlated with slower reaction times and reduced verbal memory performance. These two cognitive parameters were also associated with a reduced global health status and a reduced physical function score on the EORTC-QLQ30 questionnaire suggesting an impact of cognitive deficits on quality of life. Cognitive function was not associated with type of treatment or node status.


In this large and homogeneous cohort of breast cancer patients, CD has been shown in most of the subjects using a valid test method. CD was associated with depression and reduced quality of life. Neither tumor therapy nor other clinical parameters had a significant impact on development of CD.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.